A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Phase 4
Completed
- Conditions
- Cancer of Prostate
- Registration Number
- NCT00220194
- Lead Sponsor
- San Bernardino Urological Associates Medical Group Inc
- Brief Summary
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in advanced Prostate Cancer patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Patient with Advanced Ca, on stable dose of Lupron or Zoladex
Exclusion Criteria
- Previous exposure to Eligard.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
San bernardino Urological Associates Medical Group
🇺🇸San Bernardino, California, United States